ArticleInternational journal of clinical and experimental pathology2018
MeCP2 level is associated with hepatocellular carcinoma development in chronic hepatitis B patients under antiviral therapy.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 citations in OpenAlex.
- Article
- MeCP2 functions as a DNA methylation reader in immune homeostasis and cancer.Frontiers in epigenetics and epigenomics · 2026Review
- circFOXM1 contributes to sorafenib resistance of hepatocellular carcinoma cells by regulating MECP2 via miR-1324.Molecular therapy. Nucleic acids · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimHepatocellular carcinoma (HCC) is a common and aggressive malignant tumor with especially high prevalence in Asia. This present study aimed to investigate the association of MeCP2 with HCC development in patients with undetectable HBV DNA by antiviral therapy.
methodsWe retrospectively reviewed the 258 patients that were recruited into the present study. The control patients were matched with the HCC patients by age, gender, hepatitis e antigen (HBeAg) status, and duration of NA therapy in a 1:1:1 ratio. Area under ROC curve (AUC) was also used to compare diagnostic significance of MeCP2 using the Hanley and McNeil method.
resultsFor the entire cohort of 258 patients, MeCP2 was overexpressed in HCC tissues, which was significantly higher than that in cirrhosis and non-cirrhosis tissues (
conclusionsWe found that MeCP2 was expressed significantly higher in HCC tissues compared with cirrhosis and non-cirrhosis tissues. MeCP2 could be a novel risk marker to predict HCC development in CHB patients with profound viral suppression under NA therapy. MeCP2 measurement may serve as a useful strategy for risk stratification in terms of follow up interval and HCC surveillance.
Indexed as
Identifiers
31938231PMC6958145W3027261390What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.